[Physiopathology and drug-modification of the carcinoid syndrome].
D000818:Animals; D007611:Aprotinin / Q000627:therapeutic use; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000503:physiopathology*; D002395:Catecholamines / Q000378:metabolism / Q000652:urine; D002746:Chlorpromazine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007490:Iproniazid / Q000627:therapeutic use; D007705:Kinins / Q000378:metabolism; D008750:Methyldopa / Q000627:therapeutic use; D008784:Methysergide / Q000627:therapeutic use; D012110:Reserpine / Q000627:therapeutic use; D012701:Serotonin / Q000097:blood / Q000378:metabolism; D012702:Serotonin Antagonists
D002395:Catecholamines; D007705:Kinins; D012702:Serotonin Antagonists; D012701:Serotonin; D008750:Methyldopa; D012110:Reserpine; D003520:Cyclophosphamide; D006493:Heparin; D007611:Aprotinin; D007490:Iproniazid; D002746:Chlorpromazine; D008784:Methysergide
Pathophysiologie und medikamentöse Beeinflussung des Karzinoidsyndroms.